The original version of this article unfortunately had some missing content. The missing content is provided below. Cesare Sirtori is MD, PhD, full professor of Clinical Pharmacology and Dean of the School of Pharmacy at the University of Milan, Italy. In the 1970s, he established the Niguarda Hospital in Milan, one of the first centers (the Center E Grossi Paoletti, now Centro Universitario per le Dislipidemie) for the study of metabolic diseases with a high atherosclerosis risk, now the world's second largest lipid clinic for clinical research in hyperlipoproteinemias, thrombosis, and non-invasive monitoring of vascular lesions. He has authored over 500 scientific publications (over 300 of which on major international journals) and has reported a number of major findings, including the recognition of the first mutant of human apolipoproteins (apo A-IMilano) and the development of the concept of HDL therapy.
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